Recent share performance and business snapshot

Ensign Group (ENSG) has drawn investor attention after the stock declined about 2% over the past day and roughly 9% over the past month, with a fall of about 22% in the past 3 months.

At a recent close of US$167.65 and a market value near US$9.7b, the company generates about US$5.27b in annual revenue and US$363.36m in net income across its Skilled Services and Standard Bearer segments.

The stock’s recent 1-day, 7-day, 30-day and 90-day share price returns show that momentum has cooled in the short term, while the 1-year and multi year total shareholder returns remain firmly positive.

If this shift in sentiment has you reassessing your watchlist, it could be a good moment to broaden your search with our screener of 38 healthcare AI stocks

With Ensign Group shares down in recent months but long term returns still positive, the key question now is whether the current valuation offers a genuine entry point or if the market is already pricing in future growth.

Price-to-Earnings of 26.7x: Is it justified?

On a simple earnings lens, Ensign Group looks expensive, with a P/E of 26.7x at a last close of $167.65, while peers in its group sit closer to 14.1x and the broader US Healthcare sector at 23.2x.

The P/E ratio tells you how much investors are currently paying for each dollar of earnings. This is especially relevant for a profitable operator with recurring healthcare revenue like Ensign Group. A higher multiple often reflects expectations for future earnings growth or perceived business quality, while a lower multiple can point to more muted expectations or higher risk.

Here, the current 26.7x P/E stands well above both the peer average of 14.1x and the estimated fair P/E of 23.7x. This suggests the market is pricing Ensign Group at a premium relative to similar healthcare stocks and above the level our fair ratio model indicates the multiple could eventually move toward.

Result: Price-to-earnings of 26.7x (OVERVALUED)

However, investors still need to watch for regulatory changes in healthcare reimbursement, as well as any slowdown in annual revenue or net income growth that challenges the premium P/E story.

Another angle, using our DCF model

While the P/E points to a premium, our DCF model presents a slightly different perspective. On this view, Ensign Group at $167.65 sits just above an estimated future cash flow value of $164.13, indicating that it may be only modestly overvalued. That raises a key question: is this a margin of safety you are comfortable with?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the combination of premium valuation and modest DCF gap leaves you unsure, review the data yourself, compare it with your expectations, and consider why some investors are still focusing on 3 key rewards

Looking for more investment ideas?

If Ensign Group is on your radar, do not stop there. Expand your watchlist with other targeted ideas so you are not missing attractive opportunities.

• Target potential value opportunities by checking companies in the 46 high quality undervalued stocks that pair financial quality with appealing prices.
• Prioritise resilience by reviewing stocks in the 63 resilient stocks with low risk scores that screen well on stability and risk metrics.
• Spot less crowded opportunities by scanning the screener containing 22 high quality undiscovered gems featuring solid fundamentals away from the usual market favourites.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.